Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 2, 2009, Pages 412-417

  Zhou, Jin ^a   Cai, Zhong Hua ^a   Li, Lei ^a   Kou, Chuang ^a   Gao, Yun Feng ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Bioactivity; Exendin 4; Histological; PEGylation; Pichia pastoris

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN; MACROGOL DERIVATIVE; METHANOL; PEGYLATED EXENDIN 4; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENCY; DRUG PURIFICATION; DRUG PURITY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; KIDNEY; LARGE SCALE PRODUCTION; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS; PICHIA PASTORIS; PROTEIN EXPRESSION; RAT; TISSUE INJURY;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INSULIN; MOLECULAR SEQUENCE DATA; PEPTIDES; PICHIA; POLYETHYLENE GLYCOLS; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VENOMS;

EID: 67349188462     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.02.001     Document Type: Article

References (23)

1. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J. Biol. Chem. 267 (1992) 7402-7405
2. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
3. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
4. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Forst G.S., Leirhton J., Seal L.J., Ghatei M.A., and Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 281 (2001) 155-161
5. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., Parkes D., and Young A.A. Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa zucker rats independent of glycemia and body weight. Endocrinology 146 (2005) 2069-2076
6. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., Taylor K., Kim D., Aisporna M., Wang Y., and Baron A.D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 88 (2003) 3082-3089
7. Xu G., and Kaneto H. GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diabetes Res. Clin. Pract. 73 (2006) 107-110
8. Yi L.A., Yin X.P., Wei D.Z., and Ma Y.S. Expression and purification of exendin-4 dimer in Escherichia coli and its interaction with GLP-1 receptor in vitro. Protein Pept. Lett. 13 (2006) 823-827
9. Yin X.P., Wei D.Z., Yi L.N., Tao X.Y., and Ma Y.S. Expression and purification of exendin-4, a GLP-1 receptor agonist in Escherichia coli. Protein Expr. Purif. 41 (2005) 259-265
10. Y.P. Zhuang, H. Wang, J. Chu, Y.H. Wang. S.L. Zhang, Construction, expression and culture methods of a new glucose-lowering peptide in Pichia pastoris, Chinese Patent 2,007,100,371,336, March 2007.
11. Lee S., Youn Y.S., Lee S.H., and Lee B.K.C. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49 (2006) 1608-1611
12. Lotte B.K. Glucagon-like peptide: the basis of a new class of treatment for type-2 diabetes. J. Med. Chem. 47 (2004) 4128-4134
13. Hupe S.K., Mcgregor G.P., Bridenbaugh R., Goke R., Thole H., Zimmermann B., and Voigt K. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58 (1995) 149-156
14. Pernille S., Sven F., Simon B., Marco W., Peter K., and Horn E.M. Characterization and physical stability of PEGylated glucagons. Int. J. Pharm. 330 (2007) 89-98
15. Youn Y.S., Chae S.Y., Lee S., Jeon J.U., Shin H.G., and Lee K.C. Evaluation of therapeutic potentials os site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability and proteolytic stability. Biochem. Pharmacol. 73 (2007) 84-93
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
17. G. Wolfgang, M.J. Philip, M.R.L. Junior, V.A. Mark, L.S. Zhang, GLP-1 PEGylated compounds, US Patent A61K47/48, 2006.
18. O'Harte F.P.M., Mooney M.H., Lawlor A., and Peter R.F. N-terminally modified glucagons-like peptide-1 (7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim. Biophys. Acta 1474 (2000) 13-22
19. Patrick S.M., Fazenda M.L., and Mcneil B. Heterologous protein production using the Pichia pastoris expression system. Yeast 22 (2005) 249-270
20. Daly R., and Hearn M.T.W. Expression of heterogonous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J. Mol. Recognit. 18 (2005) 119-138
21. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
22. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
23. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae Y.C., Byun Y., and Lee K.C. Synthesis characterization and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 16 (2005) 377-382